Tradestie Institutional Equity Comparison Engine

BIIB vs ILMN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BIIB Overall Edge

BIIB Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Growth & Margin, Options & Structure while ILMN counters with relative strength in Valuation, Momentum & Technical. Fundamentally, BIIB trades at 15.6x Forward P/E with 23.5% operating margin (+10.6% YoY revenue) versus ILMN at 33.5x Forward P/E and 19.1% operating margin (+4.2% YoY). In options structure, BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against ILMN sits in CONSOLIDATION (24th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ILMN
BIIB 15.6x vs ILMN 33.5x Fwd P/E
Growth & Margin Winner BIIB
Op Margin 23.5% vs 19.1% ยท YoY +10.6% vs +4.2%
Momentum & Technical Winner ILMN
1Y +53.4% vs +66.9% ยท 52W Pos 92% vs 44%
Options & Structure Winner BIIB
CONSOLIDATION (6th %ile IV) vs CONSOLIDATION (24th %ile IV)
BIIB NASDAQ
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
1M Return +8.63%
1Y Return +53.41%
Forward P/E 15.6x
Unified AI Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
ILMN NASDAQ
Illumina Inc
Laboratory Analytical Instruments
$200.12
-3.33% 1D
Market Cap $31.7B
1M Return -23.78%
1Y Return +66.86%
Forward P/E 33.5x
Unified AI Score
55.1 / 100 HOLD
Tech 53.0 Fund 57.0 Flow 58.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BIIB +53.41% ILMN +66.86% Spread: +13.45 pp (ILMN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BIIB Revenue ILMN Revenue BIIB Op. Margin ILMN Op. Margin Margin Edge
FY2018 $13.4B $3.33B 43.8% 26.5% BIIB
FY2019 $14.4B $3.54B 49.0% 27.8% BIIB
FY2020 $13.4B N/A 33.8% N/A BIIB
FY2021 $11.0B $3.24B 25.9% 17.9% BIIB
FY2022 $10.2B $4.53B 29.9% -2.7% BIIB
FY2023 $9.84B $4.50B 11.8% -23.7% BIIB
FY2024 $9.68B $4.37B 16.9% -19.1% BIIB
FY2025 $9.89B $4.34B 13.1% 18.6% ILMN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BIIB (6) vs ILMN (4)
Institutional Metric BIIB ILMN Criterion Row Winner
Market Capitalization Scale $37.0B $31.7B Larger Scale BIIB
Trailing P/E Ratio Valuation 109.9x 36.6x Lower Multiple ILMN
Forward P/E Ratio Valuation 15.6x 33.5x Lower Multiple BIIB
Revenue Growth (YoY) Growth +10.6% +4.2% Higher Growth BIIB
Operating Margin (TTM) Profitability 23.5% 19.1% Higher Margin BIIB
Net Profit Margin Profitability 3.4% 19.7% Higher Margin ILMN
Return on Equity (ROE) Capital Efficiency 1.9% 32.4% Higher ROE ILMN
52-Week Range Position Momentum 92% ($160โ€“$261) 44% ($113โ€“$309) Stronger Trend BIIB
Beta / 30D Volatility Risk Regime 0.27ฮฒ ยท 36% Vol 1.34ฮฒ ยท 85% Vol Lower Realized Risk BIIB
Unified Institutional Score Composite Signal 50.2 / 100 (HOLD) 55.1 / 100 (HOLD) Higher Composite ILMN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BIIB vs ILMN Buy Guide
BIIB CONSOLIDATION
17d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live BIIB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ILMN CONSOLIDATION
81d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 24th %ile
IV Regime Compressed (<25th %ile)
Live ILMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BIIB nor ILMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.